Q-omics provides the consensus-scored FOXP3 profile across patient tissues and cancer cell-line models. FOXP3 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, FOXP3 is differentially expressed in 16, with the highest sampling consensus in COAD. Additionally, FOXP3 RNA expression shows 14,446 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight HNSC, COAD, and UVM as cancer lineages where FOXP3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FOXP3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FOXP3 survival associations across molecular data types. FOXP3 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (2) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FOXP3 RNA expression–survival associations across cancer types. High FOXP3 expression shows unfavorable associations in ACC and KIRC, but favorable associations in HNSC, CESC, SKCM and UCEC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for FOXP3 RNA expression.
This table summarizes FOXP3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for FOXP3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FOXP3 shows higher tumor expression in COAD, HNSC, KIRC, STAD, LUAD and UCEC. The COAD box plot shows higher FOXP3 RNA expression in tumor versus normal tissue (log2 FC = +1.374, t-test p < 0.001).
This table shows molecular features associated with FOXP3 in patient tissues and cancer cell lines. In patient samples, FOXP3 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, FOXP3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and OVARY.
